CD274 and non-small cell lung carcinoma: Subsequently, in 2016, it was approved as a first-line therapy for patients with advanced NSCLC with PD-L1 expression ≥ 50%, based on the results of the randomized phase III study KEYNOTE-024 (Table 1) [45].